278 related articles for article (PubMed ID: 14654082)
1. Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics.
Trost D; Hildebrandt B; Müller N; Germing U; Royer-Pokora B
Leuk Res; 2004 Feb; 28(2):171-7. PubMed ID: 14654082
[TBL] [Abstract][Full Text] [Related]
2. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.
Lezon-Geyda K; Najfeld V; Johnson EM
Leukemia; 2001 Jun; 15(6):954-62. PubMed ID: 11417483
[TBL] [Abstract][Full Text] [Related]
3. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
[TBL] [Abstract][Full Text] [Related]
4. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.
Bernell P; Jacobsson B; Nordgren A; Hast R
Leukemia; 1996 Apr; 10(4):662-8. PubMed ID: 8618444
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission.
Engel H; Goodacre A; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Andreeff M
Br J Haematol; 1997 Oct; 99(1):64-75. PubMed ID: 9359505
[TBL] [Abstract][Full Text] [Related]
7. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype.
Cuneo A; Bigoni R; Cavazzini F; Bardi A; Roberti MG; Agostini P; Tammiso E; Ciccone N; Mancini M; Nanni M; De Cuia R; Divona M; La Starza R; Crescenzi B; Testoni N; Rege Cambrin G; Mecucci C; Lo Coco F; Saglio G; Castoldi G
Leukemia; 2002 Sep; 16(9):1745-51. PubMed ID: 12200689
[TBL] [Abstract][Full Text] [Related]
8. DOES THE PATTERN OF CLONAL EVOLUTION IN THE KARYOTYPE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES DEPEND ON THE TYPE OF THE PRIMARY CHROMOSOMAL ABERRATIONS?
Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
Tsitol Genet; 2015; 49(4):17-24. PubMed ID: 26419065
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia.
Tamura S; Takemoto Y; Hashimoto-Tamaoki T; Mimura K; Sugahara Y; Senoh J; Furuyama JI; Kakishita E
Int J Oncol; 1998 Jun; 12(6):1259-62. PubMed ID: 9592183
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
[TBL] [Abstract][Full Text] [Related]
11. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplasia progressing to acute myeloid leukemia in monozygotic twins with monosomy 7 as sole abnormality.
Udayakumar AM; Surekhatony M; Wali YA
Leuk Lymphoma; 2014 Nov; 55(11):2672-4. PubMed ID: 24598016
[No Abstract] [Full Text] [Related]
13. Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH.
Van Limbergen H; Poppe B; Michaux L; Herens C; Brown J; Noens L; Berneman Z; De Bock R; De Paepe A; Speleman F
Genes Chromosomes Cancer; 2002 Jan; 33(1):60-72. PubMed ID: 11746988
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
[TBL] [Abstract][Full Text] [Related]
15. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.
Rigolin GM; Bigoni R; Milani R; Cavazzini F; Roberti MG; Bardi A; Agostini P; Della Porta M; Tieghi A; Piva N; Cuneo A; Castoldi G
Leukemia; 2001 Dec; 15(12):1841-7. PubMed ID: 11753603
[TBL] [Abstract][Full Text] [Related]
16. FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes.
Lessard M; Herry A; Berthou C; Léglise MC; Abgrall JF; Morice P; Flandrin G
Leuk Res; 1998 Apr; 22(4):303-12. PubMed ID: 9669835
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
[TBL] [Abstract][Full Text] [Related]
18. The monosomy 7 clone in interphase and metaphase cell population: a combined chromosome and primed in situ labeling study.
Pedersen B; Koch J; Bendix Hansen K; Hindkjaer J; Lindbjerg Andersen C
Acta Haematol; 1997; 97(4):216-21. PubMed ID: 9158664
[TBL] [Abstract][Full Text] [Related]
19. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients.
Romeo M; Chauffaille Mde L; Silva MR; Bahia DM; Kerbauy J
Leuk Res; 2002 Nov; 26(11):993-6. PubMed ID: 12363467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
